Want to see SION full AI Analyst Report?
SION Stock Chart & Stats
$43.54
$0.55(1.26%)
At close: 4:00 PM EST
$43.54
$0.55(1.26%)
Day’s Range― - ―
52-Week Range$16.38 - $48.45
Previous CloseN/A
Volume33.51K
Average Volume (3M)433.16K
Market Cap
$2.04B
Enterprise Value$1.60B
Total Cash (Recent Filing)$216.15M
Total Debt (Recent Filing)$8.38M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 17, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding45,150,330
10 Day Avg. Volume474,586
30 Day Avg. Volume433,158
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.54K
Enterprise Value/Ebitda-19.78
Forecast
1Y Price Target
$51.71Price Target Upside18.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened Balance SheetThe material equity infusion and very low debt reduce solvency risk and extend runway for clinical programs. A stronger capital base improves funding flexibility for multi-year R&D, lowers near-term refinancing pressure and supports strategic partnerships without urgent distress.
Focused CF Small-molecule StrategyConcentrated focus on cystic fibrosis and CFTR biology targets a clear, persistent unmet medical need. This niche enhances opportunity for regulatory incentives, streamlined trial design, and partnership/licensing value for differentiated therapies addressing patients outside current treatment cohorts.
Governance And Audit ContinuityReelection of board members and auditor ratification provide leadership continuity and credible financial oversight. Stable governance reduces execution risk on multi-year R&D plans, supports credible external reporting, and can ease investor, partner and lender confidence when raising future capital.
Bears Say
Pre-revenue StatusBeing pre-revenue means no product cash inflows to offset spending; long lead times to commercialization raise dependency on financing. Absent milestone/license revenues, the firm must fund development externally, increasing dilution and execution risk over the medium term.
Worsening Cash BurnRising operating cash deficits materially increase near-term financing needs and can force reprioritization of programs. Persistent heavy burn heightens exposure to capital market cycles and potential dilution, constraining strategic optionality until revenue or partnership funding arrives.
Negative Returns Despite EquityNegative ROE indicates current capital is not generating value and reflects sustained operating losses. Even with a stronger balance sheet, continued negative returns undermine long-term investor value creation and signal that operational performance must improve to justify financing.
Sionna Therapeutics, Inc. News
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $16.38 and its highest was $48.45 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $2.04B.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
Sionna Therapeutics, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 35 days.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.514 by -$0.086.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate is -0.65.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 45,150,330 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.514. Following the earnings report the stock price went down -10.903%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sionna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.71 (18.77% Upside)
$51.71 (18.77% Upside)
Blogger Sentiment
Bullish
SION Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 527.9K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.71%
12-Months-Change
Fundamentals
Return on Equity
-27.31%
Trailing 12-Months
Asset Growth
-17.48%
Trailing 12-Months
Company Description
Sionna Therapeutics, Inc.
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
SION Stock 12 Month Forecast
Average Price Target
$51.71
▲(18.77% Upside)
Technical Analysis
Stoke Therapeutics
―
Vir Biotechnology
―
Immatics
―
Tango Therapeutics
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
33.61% Insiders
9.60% Mutual Funds
<0.01% Other Institutional Investors
49.92% Public Companies and
Individual Investors